Role of some vasoactive mediators in patients with erectile dysfunction: Their relationship with angiotensin-converting enzyme and growth hormone

International Journal of Impotence Research

Volumn 15, Issue 6, 2003, Pages 418-425

  Hamed, E A ^a,c   Meki, A R M A ^a   Gaafar, A A A ^b   Hamed, S A ^a  

^a Faculty of Medicine   (Egypt)

^b ASSIUT UNIVERSITY   (Egypt)

^c Assiut University Faculty of Medicine   (Egypt)

Author keywords

Angiotensin converting enzyme; Cyclic guanosine monophosphate; Endothelin 1; Erectile dysfunction; Growth hormone; Nitric oxide

Indexed keywords

CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN 1; GROWTH HORMONE; NITRIC OXIDE; PROSTAGLANDIN E1; VASOACTIVE AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERECTILE DYSFUNCTION; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORGANIC IMPOTENCE; PATHOPHYSIOLOGY; PENILE BLOOD FLOW; PRIORITY JOURNAL; PSYCHOGENIC IMPOTENCE;

ADULT; CYCLIC GMP; DIABETIC ANGIOPATHIES; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HUMAN GROWTH HORMONE; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; NITRIC OXIDE; PENIS; PEPTIDYL-DIPEPTIDASE A; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; VASOCONSTRICTION; VASODILATION;

EID: 0345872270     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901059     Document Type: Article

References (39)

1. NIH consensus development panel on impotence. JAMA 1993; 270: 83-90.
2. Goldstein I, and the Working Group for the study of central mechanisms in erectile dysfunction. Male sexual circuitry. Sci Am 2000; 283: 70-75.
3. Araujo AB et al. Relationship between psychosocial risk factors and incident erectile dysfunction: prospective results from the Masschusetts Male Aging Study. Am J Epidemiol 2000; 152: 533-541.
4. De Nicola L, Blantz RC, Gabbai FB. Nitric oxide and angiotensin II. J Clin Invest 1992; 89: 1248-1256.
5. Rajfer J et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to noradrenergic, norcholinergic neurotransmission. N Engl J Med 1992; 325: 90-94.
6. Burnett AL. Nitric oxide in the penis: physiology and pathology. J Urol 1997; 157: 320-324.
7. Rubanyi GM, Botelho LH. Endothelins. FASEB J 1991; 5: 2713-2720.
8. Christ GJ, Lerner SE, Kim DC, Melman A. Endothelin-1 as a putative modulator of erectile dysfunction: characteristics of contraction of isolated corporal tissue strip. J Urol 1995; 153: 1998-2003.
9. Teixeira CE et al. Pharmacological characterization of kinin-induced relaxation of human corpus cavernosum. Br J Urol 1998; 81: 432-436.
10. Kifor I et al. Tissue angiotensin II as modulator of erectile function. I. Angiotensin peptide content sections and effects in the corpus cavernosum. J Urol 1997; 157: 1920-1925.
11. Hsueh WA, Tuck ML. Aldosterone and the renin-angiotensin system. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metubolism. Lippincott: Philadelphia, JB, 1990, pp 319-362.
12. Emori T et al. Cellular mechanism of endothelin-1 release of angiotenin and vasopressin. Hypertension 1991; 18: 165-171.
13. Neumann F et al. Endokrin-pharmakologie. In: Forth W et al. (eds). Allgemeine und Spezielle Pharmakologie und Toxikologie. Spektrum akadmischer Verlag: Heidelberg, 1996, p 581.
14. Becker AJ et al. Possible role of human growth hormone in penile erection. J Urol 2000; 164: 2138-2142.
15. Rosen RC et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830.
16. Goldstein I et al. Vascular diseases of the penis: impotence and priapism. In: Pollack HM (ed.) Clinical Urography, W. B. Saunders: Philadelphia, 1990.
17. Mulhall JP, Abdel-Monem A, Abobakr R, Goldstein I. Improvement the accuracy of vascular testing in impotent men: correcting hemodynamic alterations using a vasoactive medication re-dosing schedule. J Urol 2001; 166: 923-926.
18. Becker AJ, Uckert S, Stief CG, Jonas U. Plasma levels of cGMP in the cavernous and systemic blood of healthy males during different conditions of the penis. Urol Res 2001; 29: 366-370.
19. Magiure GA, Price CP. A continuous monitoring spectrophotometric method for the measurement of angiotensin converting enzyme. In human serum. Ann Clin Biochem 1985; 22: 204-210.
20. van Bezooijen RL et al. Plasma nitrate + nitrite level are regulated by ovarian steroids but do not correlate with trabecular bone mineral density in rats. J Endocrinol 1988; 159: 27-34.
21. Motulsky HJ. Analyzing Data with graphPad Prism. GraphPad software Inc.: San Diego, CA, 1999, pp 207-221.
22. Becker AJ et al. Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescene. Urology 2001; 57: 193-198.
23. Saenz de Tejada I et al. Regulation of adrenergic activity in penile corpus cavernosum. J Urol 1989; 142: 1117-1121.
24. Wetterling T, Veltrup C, Driessen M, John U. Drinking pattern and alcohol-related medical disorders. Alcohol Alcohol 1999: 34: 330-336.
25. Xie Y et al. Effect of long-term passive smoking on erectile function and penile nitric oxide synthase in the rat. J Urol 1997; 157: 1121-1126.
26. Abdel-Fadeil MR, Zedan H, Hamed EA, Abdel-Shakour M. Endothelin-1 and nitric oxide in patients with organic and psychogenic erectile dysfunction. Egyptian J Androl Reprod 2002; 16: 87-99.
27. Sullivan ME et al. Autoradiographic localization of nitric oxide synthase binding sites in normal and diabetic rat corpus cavernosum. Rur Urol 1996; 30: 506-511.
28. Johannes CB et al. Incidence of erectile dysfunction in men 40-69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 2000; 163: 460-463.
29. Daimon M et al. Increase in serum ceruloplasmin levels is correlated with a decrease of serum nitric oxide levels in type 2 diabetes. Diabetes Care 2000; 23: 559-560.
30. Maejima K et al. Increased basal levels of plasma nitric oxide in type 2 diabetic subjects. Relationship to microvascular complications. J Diabetes Complicat 2001; 15: 135-143.
31. Lue TF. Erectile dysfunction. N Engl J Med 2000; 15: 1802-1813.
32. Chang S et al. Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via Rho-Kinase β. Int J Impot Res 2003; 15: 53-62.
33. Becker AJ et al. Serum levels of human growth hormone during different penile conditions in the cavernous - and systemic blood of healthy men and patients with erectile dysfunction. Urology 2002; 59: 609-614.
34. Francavilla S et al. Endothelin-1 in diabetic and non-diabetic men with erectile dysfunction. J Urol 1997; 158: 1770-1774.
35. Rossi P et al. Comparison between plasma concentrations of testosterone, nitric oxide and endothelin 1-2 in penile and brachial venous blood: preliminary results in men with psychogenic impotence. Biomed Pharmacother 1998; 52: 308-310.
36. Kadioglu A, Memisoglu K, Sazoya O, Tuzun E. Intracavernosal endothelin levels of impotent men before and after papaverine induce erection. J Urol 1994; 151: 1107-1113.
37. Yan C, Kim D, Aizawa T, Berk BC. Functional interplay between angiotensin II and nitric oxide. Cyclic GMP as a key mediator. Arterioscler Throm Vasc Biol 2003; 23: 26-36.
38. Dohi Y et al. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 1992; 19: 131-137.
39. Park JK et al. Gene polymorphism of angiotensin converting enzyme and endothelial nitric oxide synthase in patients with erectile dysfunction. Int J Impot Res 1999; 11: 273-276.